Sharescart Research Club logo
Products
Research
Tools
About
  • Home
  • /
  • Aurobindo Pharma
Join Channel
Consolidated Standalone

Aurobindo Pharma

₹1169.7 16.7 | 1.4%

Market Cap ₹67936 Cr.

Stock P/E 19.5

P/B 1.9

Current Price ₹1169.7

Book Value ₹ 603.3

Face Value 1

52W High ₹1365

Dividend Yield 0%

52W Low ₹ 994.4

Edit Ratio

Aurobindo Pharma Research see more...

Overview Inc. Year: 1986Industry: Pharmaceuticals & Drugs

Aurobindo Pharma Ltd is an India-based pharmaceutical company. The Company develops, manufactures and distributes generic pharmaceuticals, branded specially prescribed drugs and active pharmaceutical elements. Its product portfolio is spread over seven therapeutic/product areas comprising central nervous structures (CNS), anti-retroviral, cardiovascular (CVS), antibiotics, gastroenterological, anti-diabetics and anti-allergic. It is engaged in growing a variety of oncology and hormonal products. It is growing topical as well as transdermal products within the dermatology therapeutic section. It is likewise developing approximately three depot injections based on the microsphere and nano-suspension structures. The Company is advertising its merchandise globally around 150 countries. The Company's subsidiaries consist of APL Healthcare Ltd, Auronext Pharma Private Ltd, Auro Peptides Ltd, APL Pharma Thai Ltd and Aurolife Pharma LLC, amongst others.

Read More..

Aurobindo Pharma Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Aurobindo Pharma Quarterly Results

#(Fig in Cr.) Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
Net Sales 6851 7219 7352 7580 7567 7796 7979 8382 7868 8286
Other Income 116 187 163 136 221 136 157 135 105 121
Total Income 6967 7406 7514 7716 7788 7932 8136 8517 7973 8406
Total Expenditure 5699 5846 5750 5907 5947 6230 6401 6590 6265 6608
Operating Profit 1268 1560 1764 1808 1841 1702 1735 1927 1708 1799
Interest 57 68 76 89 111 113 118 115 98 95
Depreciation 327 418 423 354 404 382 419 444 406 429
Exceptional Income / Expenses -70 0 0 -122 0 0 0 0 0 0
Profit Before Tax 815 1075 1265 1243 1325 1207 1198 1367 1205 1274
Provision for Tax 242 324 322 323 406 391 354 432 383 428
Profit After Tax 573 751 943 920 920 817 844 935 822 846
Adjustments -2 6 -6 -11 -0 1 2 -32 2 2
Profit After Adjustments 571 757 936 909 919 817 846 903 825 848
Adjusted Earnings Per Share 9.7 12.9 16 15.5 15.7 14.1 14.6 15.6 14.2 14.6

Aurobindo Pharma Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 12121 13795 14910 16463 19564 23099 24775 23455 24855 29002 31724 32515
Other Income 97 204 116 102 155 192 381 323 291 557 622 518
Total Income 12217 13998 15025 16565 19719 23290 25155 23778 25146 29559 32346 33032
Total Expenditure 9557 10607 11475 12691 15612 18234 19441 19071 21137 23159 25141 25864
Operating Profit 2660 3392 3550 3874 4107 5056 5714 4707 4009 6400 7205 7169
Interest 160 257 67 78 263 305 74 49 140 290 457 426
Depreciation 333 392 428 558 668 967 1055 1127 1245 1522 1649 1698
Exceptional Income / Expenses 0 0 0 0 -88 -26 2815 -128 0 -192 0 0
Profit Before Tax 2168 2744 3061 3241 3091 3743 7344 3373 2613 4380 5066 5044
Provision for Tax 597 721 760 818 727 899 2010 726 685 1211 1583 1597
Profit After Tax 1571 2024 2301 2423 2365 2844 5334 2647 1928 3169 3484 3447
Adjustments 5 2 0 0 0 1 1 1 -0 4 2 -26
Profit After Adjustments 1576 2025 2302 2423 2365 2845 5335 2648 1928 3173 3486 3422
Adjusted Earnings Per Share 27 34.6 39.3 41.4 40.4 48.6 91.1 45.2 32.9 54.2 60 59

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 9% 11% 7% 10%
Operating Profit CAGR 13% 15% 7% 10%
PAT CAGR 10% 10% 4% 8%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -9% 34% 8% 3%
ROE Average 11% 10% 14% 20%
ROCE Average 14% 13% 16% 20%

Aurobindo Pharma Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 5156 7287 9372 11680 13891 16825 21930 24576 26840 29843 32653
Minority's Interest 26 3 2 2 2 0 -1 -2 12 8 -6
Borrowings 1361 743 181 451 180 0 168 249 619 2135 1562
Other Non-Current Liabilities 230 -159 -79 143 178 555 639 654 248 -326 -399
Total Current Liabilities 6136 7840 6606 8666 12021 11385 10665 8156 11494 12199 14682
Total Liabilities 12910 15714 16082 20942 26271 28765 33401 33633 39213 43859 48492
Fixed Assets 3706 4180 4834 6521 8475 9396 9374 10532 11024 14493 14794
Other Non-Current Assets 905 1240 2042 2243 2464 2956 4204 4978 6643 5160 6535
Total Current Assets 8299 10294 9206 12178 15332 16413 19740 18044 21460 23772 27162
Total Assets 12910 15714 16082 20942 26271 28765 33401 33633 39213 43859 48492

Aurobindo Pharma Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 148 404 743 318 1210 1876 2747 5330 4163 4392 3385
Cash Flow from Operating Activities 1237 1420 3279 1955 1651 4381 3329 5016 2387 2435 3925
Cash Flow from Investing Activities -1398 -1445 -1787 -1927 -2903 -1568 599 -3212 -3978 -4256 -1876
Cash Flow from Financing Activities 93 365 -1915 864 1919 -1947 -1365 -2969 1814 800 120
Net Cash Inflow / Outflow -68 340 -424 892 667 866 2563 -1164 223 -1021 2169
Closing Cash & Cash Equivalent 461 744 320 1210 1876 2747 5330 4163 4392 3385 5564

Aurobindo Pharma Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 26.98 34.61 39.28 41.36 40.36 48.56 91.05 45.2 32.9 54.16 60.02
CEPS(Rs) 32.6 41.28 46.57 50.88 51.76 65.03 109.05 64.41 54.14 80.06 88.38
DPS(Rs) 4.5 2.5 2.5 2.5 2.5 3 4 9 3 4.5 0
Book NAV/Share(Rs) 88.29 124.5 159.96 199.36 237.08 287.16 374.29 419.46 458.1 509.35 562.21
Core EBITDA Margin(%) 20.89 22.85 22.76 22.86 9.86 10.29 10.98 9.17 7.31 9.77 10.36
EBIT Margin(%) 18.97 21.5 20.73 20.11 8.36 8.57 15.27 7.16 5.41 7.81 8.69
Pre Tax Margin(%) 17.66 19.67 20.28 19.64 7.71 7.92 15.11 7.05 5.14 7.33 7.97
PAT Margin (%) 12.8 14.5 15.25 14.68 5.9 6.02 10.98 5.54 3.79 5.3 5.48
Cash Profit Margin (%) 15.51 17.31 18.08 18.07 7.56 8.06 13.15 7.89 6.24 7.85 8.08
ROA(%) 14.03 14.14 14.47 13.09 10.02 10.33 17.16 7.9 5.29 7.63 7.54
ROE(%) 35.29 32.53 27.63 23.02 18.49 18.52 27.53 11.38 7.5 11.18 11.15
ROCE(%) 27.18 27.36 24.96 22.74 17.98 18.72 30.1 12.71 9.39 13.76 14.39
Receivable days 91.84 106.53 89.16 64.66 29.56 29.85 29.37 28.69 30.42 28.34 30.33
Inventory Days 88.91 100.27 101.43 112.7 59.64 57.72 62.82 63.29 57.65 55.92 58.44
Payable days 121.75 146.6 142.39 135.78 113.97 107.32 111.03 108.6 117.74 133.88 135.14
PER(x) 22.61 21.53 17.19 13.47 19.47 8.51 9.68 14.8 15.75 20.12 19.32
Price/Book(x) 6.91 5.98 4.22 2.8 3.32 1.44 2.36 1.59 1.13 2.14 2.06
Dividend Yield(%) 0.37 0.34 0.37 0.45 0.32 0.73 0.45 1.35 0.58 0.41 0
EV/Net Sales(x) 3.27 3.47 2.84 2.2 2.61 1.17 2.06 1.59 1.17 2.2 2.11
EV/Core EBITDA(x) 14.89 14.1 11.95 9.33 12.43 5.32 8.95 7.94 7.27 9.98 9.31
Net Sales Growth(%) 49.64 13.81 8.08 10.42 18.83 18.07 7.26 -5.32 5.97 16.68 9.39
EBIT Growth(%) 26.32 28.92 4.22 6.12 1.06 20.8 83.25 -53.88 -19.54 69.62 18.28
PAT Growth(%) 34.4 28.79 13.72 5.29 -2.41 20.4 87.57 -50.37 -27.18 64.4 9.93
EPS Growth(%) 34.12 28.25 13.52 5.28 -2.41 20.32 87.51 -50.36 -27.21 64.62 10.83
Debt/Equity(x) 0.86 0.69 0.36 0.41 0.5 0.33 0.23 0.1 0.18 0.21 0.24
Current Ratio(x) 1.35 1.31 1.39 1.41 1.28 1.44 1.85 2.21 1.87 1.95 1.85
Quick Ratio(x) 0.76 0.8 0.74 0.73 0.67 0.77 1 1.29 1.13 1.14 1.13
Interest Cover(x) 14.56 11.69 46.88 42.7 12.77 13.27 99.58 70.34 19.6 16.12 12.08
Total Debt/Mcap(x) 0.12 0.12 0.09 0.15 0.15 0.23 0.1 0.06 0.16 0.1 0.12

Aurobindo Pharma Shareholding Pattern

# Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
Promoter 51.83 51.83 51.83 51.83 51.8 51.82 51.82 51.82 51.82 51.82
FII 24.13 22.45 20.72 18.02 16.73 16.59 16.29 15.33 14.37 14.21
DII 15.73 18.29 20.6 23.28 24.77 25.13 25.21 26.24 26.94 27.6
Public 8.31 7.42 6.85 6.87 6.7 6.46 6.69 6.61 6.87 6.38
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Company has a low return on equity of 10% over the last 3 years.
  • Debtor days have increased from 133.88 to 135.14days.
  • The company has delivered a poor profit growth of 4% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Aurobindo Pharma News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!